drugset
drugset / Trial / NCT05403385

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385 ↗

Phase 2 Active not recruiting 36 enrolled iTeos Therapeutics iTeos Belgium SA · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.

Timeline

Start
2022-08-26
Primary completion
2025-06-13
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject inupadenant Small molecule — —
Background Carboplatin Small molecule — —
Background Pemetrexed Small molecule — —

Indications

non-small cell lung carcinoma